Saama acquires Comprehend, combining strengths and elevating ability to innovate
The clinical data analytics companies will see an increase in their combined market share and expansion of existing partner ecosystems.
“Together Saama and Comprehend will elevate the ability of life science companies to incorporate and leverage patient-centric data analytics regarding drug safety and efficacy for optimal clinical operations and outcomes,” said Suresh Katta, founder and chairman of Saama.
“Saama’s acquisition of Comprehend creates an exciting, enhanced suite of complementary capabilities that further empower life sciences companies to create and conduct patient-centric trials that expedite the development and availability of therapeutics to improve global health,” Katta told us.
The acquisition – financial terms of which were not disclosed – closed on Monday, August 12.
The brands will be integrated in the long run “to combine strengths and elevate their ability to innovate and deploy cutting-edge, AI-powered clinical development solutions and software that empower biopharma to facilitate more rapid drug development,” explained Sagar Anisingaraju, chief strategy officer, Saama.
“In the short term, the integration will be driven by what is optimal and appropriate for sponsors and CROs who are using their products,” he told us.
Saama earlier this year closed a $40m financing with Perceptive Advisors, a NY-based firm that focuses on supporting the life sciences industry. Since 2015, The clinical data analytics platform firm has raised $75m.
Katta previously told us the funding will be used to further invest in and expand the company’s Life Science Analytics Cloud (LSAC). The platform is powered by artificial intelligence (AI) to support clinical trial design and conduct across various development stages, according to the company.
Comprehend’s Clinical Intelligence Platform (CIP) is aimed at supporting contract research organization’s (CROs) needs through analytics and continuous data aggregation. The platform also allows for CROs to adhere to ICH E6(R2).
Comprehend also yesterday announced a partnership with the Rockville, Maryland-based contract research organization (CRO) DP Clinical, which will deploy Comprehend's Centralized Monitoring solution.
Devinder Poonian, president and CEO of DP Clinical, told us the company researched and tested several centralized monitoring software options over the last couple of years before partnering with Comprehend on a global project.
"We were looking for a solution that offered a streamlined approach to risk-based monitoring, incorporated end-user functionality that provided a smooth workflow for reviewers, was relatively easy to learn and adopt internally, and was at a price point DP Clinical and our clients could accommodate," she said.
